Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far
Pivotal Trial Likely To Include Consolidation Dosing
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
You may also be interested in...
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.